Marla Dubinsky, MD, on Risk Stratification in Crohn's Disease
Dr Dubinsky stresses that virtually all patients with Crohn's disease should be treated quickly after diagnosis with approved and effective therapies—which do not include 5-ASAs— to help prevent complications and change the natural history of their disease.
Marla Dubinsky, MD, is a professor of Pediatrics and Medicine (Gastroenterology) at the Icahn School of Medicine and chief of Division of Pediatric Gastroenterology at Mount Sinai Kravis Children's Hospital in New York, New York.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the AIBD Network or HMP Global, its employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of care for patients with inflammatory bowel disease.
The APP Institute | IBD is designed for Advanced Practice Providers who specialize in Inflammatory Bowel Diseases, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with IBD. Engage year-round with the AIBD Network to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
